AVB-500, our lead product candidate, is an ultra-high affinity decoy protein that targets the GAS6/AXL signaling pathway. By capturing circulating and bound GAS6, AVB-500 starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression.
In preclinical studies, AVB-500 has been shown to suppress serum GAS6 to undetectable levels thereby stopping disease progression. AVB-500’s impressive safety and tolerability profile suggests it could be ideal for use in combination or as a maintenance therapy. Our proprietary biomarker is supporting development of AVB-500 in multiple indications where GAS6/AXL signaling has been implicated, including ovarian cancer and kidney fibrosis, specifically immunoglobulin A nephropathy (IgAN).
Aravive is based in Houston, Texas, where it relocated after receiving a $20 million Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016.